Loading
The trial that brought HER2 testing and trastuzumab to stomach cancer: adding the antibody to chemotherapy prolonged survival in patients whose gastric or junction cancers overexpressed HER2, about a fifth of those screened.
ToGA screened 3,665 patients with advanced gastric or gastro-oesophageal junction cancer and found HER2 positivity in 22.1%. It randomised 594 HER2-positive patients to trastuzumab plus cisplatin and a fluoropyrimidine or to chemotherapy alone. Trastuzumab improved overall survival, progression-free survival and response rate, with the largest benefit in tumours with high HER2 expression (immunohistochemistry 3+ or 2+ with amplification), which became the definition of HER2 positivity used for gastric cancer.
ToGA made gastric cancer the second disease treated by HER2 status and introduced gastric-specific HER2 scoring. It is the base on which trastuzumab deruxtecan and pembrolizumab combinations in HER2-positive gastric cancer have built.
Shares ToGA, HER2-positive gastric cancer, Trastuzumab, HER2.
Shares HER2-positive gastric cancer, Trastuzumab, Fluorouracil (5-FU), Capecitabine.
Shares HER2-positive gastric cancer, Trastuzumab, Fluorouracil (5-FU), Capecitabine.
Shares HER2-positive gastric cancer, Trastuzumab, Capecitabine, Cisplatin.
Shares HER2-positive gastric cancer, HER2, Gastric & gastro-oesophageal junction cancer.
Shares HER2-positive (IHC 3+ or ISH-amplified), HER2-positive gastric cancer, Immunohistochemistry (IHC), Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab, HER2, Gastric & gastro-oesophageal junction cancer.
Shares Yung-Jue Bang, Overall survival (OS), Immunohistochemistry (IHC), Gastric & gastro-oesophageal junction cancer.